カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の放射線療法市場（～2028年）：種類別（製品、サービス）、技術別（MRIリニアック、定位、粒子線治療、コバルト60線治療）、処置別（IMRT、IGRT、3D-CRT、LDR、HDR）、用途別（前立腺、乳房、肺）、エンドユーザー別（病院）、地域別

◆英語タイトル：Radiotherapy Market by Type (Product, Service), Technology (MRI LINAC, Stereotactic, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT, 3D-CRT, LDR, HDR), Application (Prostate, Breast, Lung), End User (Hospital) & Region - Global Forecast to 2028
	◆商品コード：MD1773-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年11月10日 ◆ページ数：277 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥742,500	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥997,500	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,222,500	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

“世界の放射線療法市場は2023年の69億米ドルから2028年には88億米ドルに達すると予測され、予測期間中の年平均成長率は5.0％"”世界的な癌罹患率の上昇、放射線療法技術の進歩、世界的な癌センターにおける粒子線治療の採用拡大が、予測期間中の放射線療法市場の成長を支えていると考えられます。

“世界の放射線療法市場のソフトウェア＆サービス分野が予測期間中に最も高いCAGRで成長”
放射線療法市場は、タイプに基づいて、製品とソフトウェア＆サービスに区分されます。ソフトウェア＆サービス分野は、主に北米やヨーロッパなどの確立された市場で高い成長率を記録する見込みです。放射線療法の進歩や、より正確で個別化されたがん治療計画への需要の高まりが、革新的な放射線療法ソフトウェア＆サービスの開発につながっています。

“技術別では、外部ビーム放射線療法分野が2022年の世界の放射線療法システム市場で最大の市場シェアを占める"
技術に基づき、放射線療法市場は外部ビーム放射線療法と内部ビーム放射線療法に区分されています。外部ビーム放射線療法（EBRT）セグメントは、外部ビーム放射線療法技術が広く採用されていること、および先進的な外部ビーム放射線療法技術の開発と商業化のために市場プレーヤーが研究開発に継続的に投資していることから、2022年に放射線療法の最大シェアを占めました。

“前立腺がん、外部ビーム放射線療法用途別で、2022年に最大の市場シェアを占める"
放射線療法市場は、用途に基づき、外部ビーム放射線療法用途と内部ビーム放射線療法/ブラキセラピー用途の2つの主要セグメントに分類されます。
外部ビーム放射線療法の用途は、さらに乳がん、前立腺がん、頭頸部がん、肺がん、大腸がん、その他のがんに分類されます。

“体内照射療法/小線源治療の用途は、前立腺がん、婦人科がん、乳がん、子宮頸がん、陰茎がん、その他のがん（肺がん、頭頸部がん）にさらに細分化”
前立腺がんは、世界的な前立腺がん罹患率の増加、前立腺がんに対する外部ビーム放射線療法の利点、前立腺がん治療のための放射線療法分野における研究活動の増加により、2022年に最大の市場シェアを占めました。

“放射線療法市場の地域別シェアは北米が最大”
世界の放射線療法市場は、北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカの5つの主要地域に区分されます。北米は放射線療法製品・サービスの最大地域市場であるのに対し、アジア太平洋市場は予測期間中に最も高いCAGRで成長すると推定されています。北米の最大シェアは、先進的な放射線療法技術の急速な採用、放射線療法ソフトウェアメーカーとエンドユーザー間の協力関係の増加、北米各国の医療施設とサービスの多様なネットワークの存在、同地域のがん治療をサポートする有利な償還モデルに起因しています。

本レポートの主な参加企業の内訳は以下の通りです：
- 企業タイプ別：ティア1-48％、ティア2-36％、ティア3-16％
- 役職別：Cレベル-10％、ディレクターレベル-14％、その他-76％
- 地域別：北米-40％、ヨーロッパ-32％、アジア太平洋-20％、中南米-5％、中東・アフリカ-3％

放射線療法市場における主なプレーヤーは、Siemens Healthcare GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), C-RAD (Sweden), IBA Worldwide (Belgium), Hitachi Ltd. (Japan (US), Mevion Medical Systems (US), Optivus Proton Therapy, Inc. (US) and Panacea Medical Technologies Pvt. Ltd. (India)などが含まれます。

調査範囲:
この調査レポートは、放射線療法市場を製品、技術、用途、エンドユーザー、地域別に調査しています。また、市場成長に影響を与える要因を網羅し、市場における様々な機会と課題を分析し、市場リーダー向けに競争環境の詳細を提供します。さらに、個々の成長動向に関してミクロ市場を分析し、4つの主要地域（およびこれらの地域のそれぞれの国）に関して市場セグメントの収益を予測しています。

レポート購入の理由:
本レポートは、既存企業だけでなく、新規参入企業や小規模企業も市場の動向を把握することができ、ひいては、より大きな市場シェアを獲得するのに役立ちます。本レポートを購入された企業は、以下の戦略の1つまたは複数を組み合わせて使用することで、市場での存在感を高めることができます。

本レポートは、以下のポイントに関する洞察を提供します：
- 放射線療法市場の成長に影響を与える主な促進要因（技術の進歩、がん有病率の上昇、粒子線治療の利用拡大）、阻害要因（適切な医療の不足、自動放射線療法システムの高コスト、熟練した放射線科医の不足）、機会（発展途上国における医療費の上昇）、課題（放射線被ばくのリスク）の分析を提供しています。
 市場の浸透：放射線療法市場のトップ企業が提供する製品ポートフォリオに関する包括的情報を掲載しています。
 製品開発/イノベーション：放射線療法市場における今後の動向、研究開発活動、製品発売に関する詳細な洞察を記載しています。
 市場開発：有利な新興地域に関する包括的情報を掲載しています。
 市場の多様化：放射線療法市場における新製品、成長地域、最新動向に関する網羅的情報を掲載しています。
 競合評価：市場セグメント、成長戦略、収益分析、主要市場プレイヤーの製品に関する詳細な評価を提供しています。

1.　イントロダクション
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6.　世界の放射線療法市場規模：製品・サービス別
7.　世界の放射線療法市場規模：技術別
8.　世界の放射線療法市場規模：用途別
9.　世界の放射線療法市場規模：処置別
10.　世界の放射線療法市場規模：エンドユーザー別
11.　世界の放射線療法市場規模：地域別
12.　競争環境
13.　企業情報
14.　付録

❖ レポートの目次 ❖

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.2.1 INCLUSIONS AND EXCLUSIONS 36
1.3 STUDY SCOPE 37
1.3.1 MARKETS COVERED 37
1.3.2 REGIONS COVERED 38
1.3.3 YEARS CONSIDERED 38
1.3.4 CURRENCY CONSIDERED 38
1.4 KEY STAKEHOLDERS 39
1.5 SUMMARY OF CHANGES 39
1.6 RECESSION IMPACT 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
FIGURE 1 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY RESEARCH 42
2.1.2.1 Key data from primary sources 42
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 43
FIGURE 3 GLOBAL RADIOTHERAPY MARKET: BREAKDOWN OF PRIMARIES 43
2.2 MARKET SIZE ESTIMATION METHODOLOGY 43
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 44
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 44
2.2.2 USAGE-BASED MARKET ESTIMATION 45
FIGURE 5 MARKET SIZE ESTIMATION: GLOBAL RADIOTHERAPY MARKET 45
2.2.3 PRIMARY RESEARCH VALIDATION 46
2.3 DATA TRIANGULATION 47
FIGURE 6 DATA TRIANGULATION METHODOLOGY 47
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 48
2.4.1 RESEARCH ASSUMPTIONS 48
2.4.2 RESEARCH LIMITATIONS 48
2.5 RECESSION IMPACT ANALYSIS 48
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 48

3 EXECUTIVE SUMMARY 50
FIGURE 7 RADIOTHERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 8 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 51
FIGURE 9 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 10 RADIOTHERAPY MARKET SHARE, BY END USER, 2023 VS. 2028 52
FIGURE 11 RADIOTHERAPY MARKET: GEOGRAPHICAL SNAPSHOT 53
4 PREMIUM INSIGHTS 54
4.1 RADIOTHERAPY MARKET OVERVIEW 54
FIGURE 12 RISING CANCER PREVALENCE WORLDWIDE TO DRIVE GROWTH 54
4.2 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 55
4.3 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TECHNOLOGY AND REGION (2022) 55
FIGURE 13 LINACS HELD LARGEST SHARE IN 2O22 55
4.4 RADIOTHERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
FIGURE 14 CHINA TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
FIGURE 15 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
5.2.1 DRIVERS 58
5.2.1.1 Advancements in radiotherapy treatment technology 58
5.2.1.2 Growing patient population 59
FIGURE 16 PROJECTED INCREASE IN CANCER CASES, 2020–2040 59
5.2.1.3 Increasing initiatives to promote radiotherapy awareness 59
5.2.1.4 Growing use of particle therapy for cancer treatment 60
5.2.2 RESTRAINTS 60
5.2.2.1 Lack of adequate healthcare infrastructure 60
5.2.2.2 High capital cost of radiotherapy 61
5.2.2.3 Complexity of radiotherapy 61
5.2.3 OPPORTUNITIES 62
5.2.3.1 Emerging economies 62
5.2.3.2 Favorable changes in US radiotherapy payment model 62
5.2.3.3 Government and private investments to meet rising demand for cancer treatment 63
5.2.4 CHALLENGES 63
5.2.4.1 Dearth of skilled personnel 63
5.2.4.2 Difficulties in visualizing tumors during radiotherapy 64
5.2.4.3 Risk of radiation exposure 64
5.3 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 2 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.3.1 THREAT OF NEW ENTRANTS 65
5.3.2 THREAT OF SUBSTITUTES 65
5.3.3 BARGAINING POWER OF SUPPLIERS 65
5.3.4 BARGAINING POWER OF BUYERS 65
5.3.5 DEGREE OF COMPETITION 66
5.4 REGULATORY LANDSCAPE 66
TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
5.4.1 NORTH AMERICA 67
5.4.1.1 US 67
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 68
5.4.2 CANADA 68
TABLE 7 CLASS II PRESCRIBED EQUIPMENT CERTIFICATES 68
5.4.3 EUROPE 69
5.4.4 ASIA PACIFIC 70
5.4.4.1 China 70
5.4.4.2 Japan 70
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 71
5.4.5 INDIA 71
5.5 REIMBURSEMENT SCENARIO 71
TABLE 9 CPT CODES FOR MAJOR RADIOTHERAPY TREATMENT MODALITIES 72
TABLE 10 REIMBURSEMENT FOR RADIOTHERAPY PROCEDURES PER COURSE, 2021 VS 2022 72
TABLE 11 OPPS TECHNICAL PER PROCEDURE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS 2022 73
TABLE 12 FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS 2022 73
5.6 ECOSYSTEM/MARKET MAP 74
5.7 VALUE CHAIN ANALYSIS 74
5.7.1 RESEARCH & DEVELOPMENT 74
5.7.2 PROCUREMENT AND PRODUCT DEVELOPMENT 74
5.7.3 MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES 74
FIGURE 17 VALUE CHAIN ANALYSIS 75
5.8 SUPPLY CHAIN ANALYSIS 75
5.8.1 PROMINENT COMPANIES 75
5.8.2 SMALL & MEDIUM-SIZED ENTERPRISES 75
5.8.3 END USERS 76
FIGURE 18 SUPPLY CHAIN ANALYSIS 76
5.9 TRADE DATA 76
TABLE 13 IMPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2017–2021 (USD MILLION) 76
TABLE 14 EXPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2017–2021 (USD MILLION) 77
5.10 PRICING ANALYSIS 77
FIGURE 19 AVERAGE SELLING PRICES OF KEY PLAYERS FOR TOP TWO PRODUCTS 77
TABLE 15 AVERAGE SELLING PRICES OF KEY PLAYERS FOR TOP TWO PRODUCTS (USD) 78
TABLE 16 AVERAGE SELLING PRICE TRENDS 78
5.11 KEY CONFERENCES & EVENTS IN 2023–2025 78
TABLE 17 RADIOTHERAPY MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS 78
5.12 TECHNOLOGY ANALYSIS 80
5.13 PATENT ANALYSIS 81
FIGURE 20 TOP PATENT APPLICANTS FOR PROTON BEAM THERAPY, JANUARY 2012–OCTOBER 2023 81
FIGURE 21 TOP PATENT APPLICANTS FOR MEDICAL LINEAR ACCELERATORS, JANUARY 2012–OCTOBER 2023 82
5.14 CASE STUDY ANALYSIS 82
TABLE 18 CASE STUDY: ENHANCING PATIENT SAFETY—SBRT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC) 82
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 83
FIGURE 22 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 83
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 83
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY SYSTEMS 83
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY DEVICES 84
5.16.2 BUYING CRITERIA 84
FIGURE 24 KEY BUYING CRITERIA FOR RADIOTHERAPY 84
TABLE 20 KEY BUYING CRITERIA FOR RADIOTHERAPY 84
6 RADIOTHERAPY MARKET, BY PRODUCT & SERVICE 85
6.1 INTRODUCTION 86
TABLE 21 RADIOTHERAPY MARKET, BY PRODUCT & SERVICE, 2022–2028 (USD MILLION) 86
6.2 PRODUCTS 86
6.2.1 CONTINUOUS DEVELOPMENT OF ADVANCED TECHNOLOGIES TO BOOST MARKET 86
TABLE 22 RADIOTHERAPY PRODUCTS MARKET, BY REGION, 2022–2028 (USD MILLION) 87

6.3 SOFTWARE & SERVICES 87
6.3.1 INCREASING DEMAND FOR PRECISE AND EFFECTIVE CANCER TREATMENT TO SUPPORT MARKET GROWTH 87
TABLE 23 RADIOTHERAPY SOFTWARE & SERVICES MARKET, BY REGION, 2022–2028 (USD MILLION) 88
7 RADIOTHERAPY MARKET, BY TECHNOLOGY 89
7.1 INTRODUCTION 90
TABLE 24 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 90
7.2 EXTERNAL BEAM RADIOTHERAPY 90
TABLE 25 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 90
TABLE 26 EXTERNAL BEAM RADIOTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 91
7.3 LINACS 91
TABLE 27 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 91
TABLE 28 LINACS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
7.3.1 CONVENTIONAL LINACS 92
7.3.1.1 Long treatment duration to limit adoption 92
TABLE 29 CONVENTIONAL LINACS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
7.3.2 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS 93
TABLE 30 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2021–2028 (USD MILLION) 93
TABLE 31 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY REGION, 2021–2028 (USD MILLION) 93
7.3.2.1 CyberKnife 94
7.3.2.1.1 Precise radiation delivery with robotic correction capabilities to drive market 94
TABLE 32 CYBERKNIFE MARKET, BY REGION, 2021–2028 (USD MILLION) 94
7.3.2.2 Gamma Knife 95
7.3.2.2.1 Ongoing product development and launches to support growth 95
TABLE 33 GAMMA KNIFE MARKET, BY REGION, 2021–2028 (USD MILLION) 95
7.3.2.3 TomoTherapy 96
7.3.2.3.1 High installation and maintenance costs to limit adoption 96
TABLE 34 TOMOTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 96
7.3.3 MRI LINACS 96
7.3.3.1 Real-time imaging advantage to propel growth 96
TABLE 35 MRI LINACS MARKET, BY REGION, 2022–2028 (USD MILLION) 97
7.4 PARTICLE THERAPY 97
TABLE 36 PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2021–2028 (USD MILLION) 97
TABLE 37 PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 98
7.4.1 CYCLOTRONS 98
7.4.1.1 Enhanced outcomes and other advantages to boost adoption 98
TABLE 38 CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 99
7.4.2 SYNCHROTRONS 99
7.4.2.1 Increasing investments in synchrotron facilities to drive market 99
TABLE 39 SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
7.4.3 SYNCHROCYCLOTRONS 100
7.4.3.1 High space requirements limit widespread adoption 100
TABLE 40 SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
7.5 CONVENTIONAL COBALT-60 TELETHERAPY 101
7.5.1 COMPLEX DOSE DELIVERY PLANNING AND RADIATION EXPOSURE TO LIMIT MARKET ADOPTION 101
TABLE 41 CONVENTIONAL COBALT-60 TELETHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 101
7.6 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 102
TABLE 42 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 43 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 102
7.7 SEEDS 103
7.7.1 ADVERSE SIDE-EFFECTS ASSOCIATED WITH SEEDS TO LIMIT ADOPTION 103
TABLE 44 SEEDS MARKET, BY REGION, 2021–2028 (USD MILLION) 103
7.8 AFTERLOADERS 103
7.8.1 PROPER POSITIONING AND BETTER CONTROL OF ISOTOPES IN MODERN AFTERLOADERS TO DRIVE DEMAND 103
TABLE 45 AFTERLOADERS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
7.9 IORT SYSTEMS 104
7.9.1 RISING ADOPTION OF ELECTRONIC BRACHYTHERAPY PROCEDURES TO SUPPORT GROWTH 104
TABLE 46 IORT SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 105
7.10 APPLICATORS 105
7.10.1 HIGH RISK OF RADIATION EXPOSURE IN MANUAL APPLICATORS TO LIMIT GROWTH 105
TABLE 47 APPLICATORS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
7.11 SYSTEMIC RADIOTHERAPY 106
7.11.1 HIGH RISK OF RADIATION EXPOSURE TO LIMIT ADOPTION 106
7.11.2 IOBENGUANE (I-131) 106
7.11.3 SAMARIUM-153 107
7.11.4 RHENIUM-186 107
7.11.5 OTHER SYSTEMIC RADIOTHERAPY PRODUCTS 107
8 RADIOTHERAPY MARKET, BY APPLICATION 108
8.1 INTRODUCTION 109
TABLE 48 RADIOTHERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 109
8.2 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 109
TABLE 49 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 109
TABLE 50 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2028 (USD MILLION) 110
8.2.1 PROSTATE CANCER 110
8.2.1.1 High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth 110
TABLE 51 EXTERNAL BEAM RADIOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 111
8.2.2 BREAST CANCER 111
8.2.2.1 Therapeutic benefits of EBRT to drive market 111
TABLE 52 EXTERNAL BEAM RADIOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 112
8.2.3 LUNG CANCER 112
8.2.3.1 High prevalence of lung cancer and efficiency of EBRT to drive market 112
TABLE 53 EXTERNAL BEAM RADIOTHERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 113
8.2.4 HEAD & NECK CANCER 113
8.2.4.1 Noninvasive treatment of head & neck cancers to drive market 113
TABLE 54 EXTERNAL BEAM RADIOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2021–2028 (USD MILLION) 113
8.2.5 COLORECTAL CANCER 114
8.2.5.1 High incidence of colorectal cancer to support market growth 114
TABLE 55 EXTERNAL BEAM RADIOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 2021–2028 (USD MILLION) 114
8.2.6 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 114
TABLE 56 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2028 (USD MILLION) 115
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 115
TABLE 57 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 115
TABLE 58 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 116
8.3.1 PROSTATE CANCER 116
8.3.1.1 Precision of brachytherapy to drive market 116
TABLE 59 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2022–2028 (USD MILLION) 117
8.3.2 GYNECOLOGICAL CANCER 117
8.3.2.1 Availability of alternatives to hinder adoption of brachytherapy 117
TABLE 60 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2021–2028 (USD MILLION) 118
8.3.3 BREAST CANCER 118
8.3.3.1 Wide usage as replacement for traditional EBRT to drive market 118
TABLE 61 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 119
8.3.4 CERVICAL CANCER 119
8.3.4.1 Effectiveness of combined brachytherapy-chemotherapy procedure to support adoption 119
TABLE 62 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR CERVICAL CANCER, BY REGION, 2021–2028 (USD MILLION) 120
8.3.5 PENILE CANCER 120
8.3.5.1 Rising awareness and effectiveness of brachytherapy to drive market 120
TABLE 63 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET FOR PENILE CANCER, BY REGION, 2021–2028 (USD MILLION) 121
8.3.6 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 121
TABLE 64 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 122
9 RADIOTHERAPY MARKET, BY PROCEDURE 123
9.1 INTRODUCTION 124
TABLE 65 RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2028 (USD MILLION) 124
9.2 EXTERNAL BEAM RADIOTHERAPY 124
TABLE 66 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 67 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY REGION, 2021–2028 (USD MILLION) 125
9.2.1 IMRT 125
9.2.1.1 Advantages over 2D and 3D-CRT to boost adoption 125
TABLE 68 IMRT MARKET, BY REGION, 2021–2028 (USD MILLION) 126
9.2.2 IGRT 126
9.2.2.1 Growing demand in treating deep-seated tumors to drive market 126
TABLE 69 IGRT MARKET, BY REGION, 2021–2028 (USD MILLION) 127
9.2.3 3D CONFORMAL RADIOTHERAPY 127
9.2.3.1 High precision and minimized damage to nearby tissues to boost adoption 127
TABLE 70 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 128
9.2.4 SRT 128
9.2.4.1 Minimally invasive procedure to drive end-user preference 128
TABLE 71 SRT MARKET, BY REGION, 2021–2028 (USD MILLION) 129
9.2.5 PARTICLE THERAPY 129
9.2.5.1 High usage as primary mode of cancer treatment to sustain market growth 129
TABLE 72 PARTICLE THERAPY MARKET, BY REGION, 2022–2028 (USD MILLION) 130
9.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 130
TABLE 73 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 74 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY REGION, 2021–2028 (USD MILLION) 131
9.3.1 LDR BRACHYTHERAPY 131
9.3.1.1 Low risk of radiation exposure to surrounding tissues to drive adoption 131
TABLE 75 LDR BRACHYTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 132
9.3.2 HDR BRACHYTHERAPY 132
9.3.2.1 Possibility of tissue injury to affect adoption 132
TABLE 76 HDR BRACHYTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 132
9.3.3 PDR BRACHYTHERAPY 133
9.3.3.1 Combination of advantages to boost growth 133
TABLE 77 PULSED-DOSE-RATE BRACHYTHERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 133
9.4 SYSTEMIC RADIOTHERAPY 133
9.4.1 HIGH COST OF RADIOPHARMACEUTICALS AND RISK OF RADIATION EXPOSURE TO LIMIT USAGE 133
9.4.2 INTRAVENOUS RADIOTHERAPY 134
9.4.3 ORAL RADIOTHERAPY 134
9.4.4 INSTILLATION RADIOTHERAPY 134
10 RADIOTHERAPY MARKET, BY END USER 135
10.1 INTRODUCTION 136
TABLE 78 RADIOTHERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 136
10.2 HOSPITALS 136
10.2.1 HOSPITALS TO DOMINATE END-USER MARKET 136
TABLE 79 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 137
10.3 INDEPENDENT RADIOTHERAPY CENTERS 137
10.3.1 LOWER OPERATING COSTS AND CONVENIENCE TO SUPPORT MARKET GROWTH 137
TABLE 80 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2021–2028 (USD MILLION) 137
11 RADIOTHERAPY MARKET, BY REGION 138
11.1 INTRODUCTION 139
TABLE 81 RADIOTHERAPY MARKET, BY REGION, 2022–2028 (USD MILLION) 139
11.2 NORTH AMERICA 139
11.2.1 NORTH AMERICA: RECESSION IMPACT 139
FIGURE 25 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT 140
TABLE 82 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 141
TABLE 83 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 141
TABLE 84 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 141
TABLE 85 NORTH AMERICA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 142
TABLE 86 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 142
TABLE 87 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 142
TABLE 88 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 143
TABLE 89 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 143
TABLE 90 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 144
TABLE 91 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 144
11.2.2 US 144
11.2.2.1 Changes in reimbursement scenario to drive market growth 144
TABLE 92 US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 145
TABLE 93 US: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 146
TABLE 94 US: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 146
TABLE 95 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 146
11.2.3 CANADA 147
11.2.3.1 Growing prevalence of cancer to drive demand for radiotherapy 147
TABLE 96 CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 147
TABLE 97 CANADA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 148
TABLE 98 CANADA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 148
TABLE 99 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 148
11.3 EUROPE 149
11.3.1 EUROPE: RECESSION IMPACT 149
TABLE 100 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 150
TABLE 101 EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 150
TABLE 102 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 150
TABLE 103 EUROPE: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 151
TABLE 104 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 151
TABLE 105 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 151
TABLE 106 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 152
TABLE 107 EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 152
TABLE 108 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 153
TABLE 109 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 153
11.3.2 GERMANY 153
11.3.2.1 Availability of novel radiotherapy products to drive market 153
TABLE 110 GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 154
TABLE 111 GERMANY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 155
TABLE 112 GERMANY: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 155
TABLE 113 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 155
11.3.3 FRANCE 156
11.3.3.1 High purchasing & maintenance costs of advanced radiotherapy systems to limit market growth 156
TABLE 114 FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 156
TABLE 115 FRANCE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 156
TABLE 116 FRANCE: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 157
TABLE 117 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 157
11.3.4 UK 157
11.3.4.1 High healthcare expenditure to drive market 157
TABLE 118 UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 158
TABLE 119 UK: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 158
TABLE 120 UK: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 159
TABLE 121 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 159
11.3.5 SPAIN 159
11.3.5.1 Growing research activities on cancer care drive market 159
TABLE 122 SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 160
TABLE 123 SPAIN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 161
TABLE 124 SPAIN: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 161
TABLE 125 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 161
11.3.6 ITALY 162
11.3.6.1 High number of oncology-specific clinical trials & studies to support market growth 162
TABLE 126 ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 162
TABLE 127 ITALY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 163
TABLE 128 ITALY: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 163
TABLE 129 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 163
11.3.7 REST OF EUROPE 164
TABLE 130 REST OF EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 164
TABLE 131 REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 164
TABLE 132 REST OF EUROPE: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 165
TABLE 133 REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 165
11.4 ASIA PACIFIC 165
11.4.1 ASIA PACIFIC: RECESSION IMPACT 166
FIGURE 26 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT 167
TABLE 134 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 168
TABLE 135 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 168
TABLE 136 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 169
TABLE 137 ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 169
TABLE 138 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 170
TABLE 139 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 170
TABLE 140 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 171
TABLE 141 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 171
TABLE 142 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 172
TABLE 143 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 172
11.4.2 JAPAN 172
11.4.2.1 Rising geriatric population and cancer incidence to drive market 172
TABLE 144 JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 173
TABLE 145 JAPAN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 173
TABLE 146 JAPAN: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 174
TABLE 147 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 174
11.4.3 CHINA 174
11.4.3.1 Growing partnerships among market players to support growth 174
TABLE 148 CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 175
TABLE 149 CHINA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 175
TABLE 150 CHINA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 176
TABLE 151 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 176
11.4.4 INDIA 176
11.4.4.1 High need for radiotherapy systems to provide opportunities 176
TABLE 152 INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 177
TABLE 153 INDIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 177
TABLE 154 INDIA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 178
TABLE 155 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 178
11.4.5 SOUTH KOREA 178
11.4.5.1 Increasing incidence of cancer to support market 178
TABLE 156 SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 179
TABLE 157 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 179
TABLE 158 SOUTH KOREA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 180
TABLE 159 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 180
11.4.6 AUSTRALIA 180
11.4.6.1 Availability of funding for cancer care & research to drive growth 180
TABLE 160 AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 181
TABLE 161 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 181
TABLE 162 AUSTRALIA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 182
TABLE 163 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 182
11.4.7 REST OF ASIA PACIFIC 182
TABLE 164 REST OF ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 183
TABLE 165 REST OF ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 183
TABLE 166 REST OF ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 184
TABLE 167 REST OF ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 184
11.5 LATIN AMERICA 184
11.5.1 LATIN AMERICA: RECESSION IMPACT 185
TABLE 168 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 185
TABLE 169 LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 185
TABLE 170 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 186
TABLE 171 LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 186
TABLE 172 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 186
TABLE 173 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 187
TABLE 174 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2023–2028 (USD MILLION) 187
TABLE 175 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 188
TABLE 176 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 188
TABLE 177 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 189
11.5.2 BRAZIL 189
11.5.2.1 Restricted affordability & access to radiotherapy to challenge market growth 189
TABLE 178 BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 189
TABLE 179 BRAZIL: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 190
TABLE 180 BRAZIL: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 190
TABLE 181 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 190
11.5.3 MEXICO 191
11.5.3.1 Rising target population to boost market growth 191
TABLE 182 MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 191
TABLE 183 MEXICO: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 192
TABLE 184 MEXICO: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 192
TABLE 185 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 192
11.5.4 REST OF LATIN AMERICA 193
TABLE 186 REST OF LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 193
TABLE 187 REST OF LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 193
TABLE 188 REST OF LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 194
TABLE 189 REST OF LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 194
11.6 MIDDLE EAST & AFRICA 194
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 194
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 195
TABLE 190 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2028 (USD MILLION) 195
TABLE 191 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2028 (USD MILLION) 196
TABLE 192 MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 196
TABLE 193 MIDDLE EAST & AFRICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2028 (USD MILLION) 196
TABLE 194 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2028 (USD MILLION) 197
TABLE 195 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY PRODUCT TYPE, 2022–2028 (USD MILLION) 197
TABLE 196 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 198
TABLE 197 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2028 (USD MILLION) 198
TABLE 198 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY END USER, 2022–2028 (USD MILLION) 199
12 COMPETITIVE LANDSCAPE 200
12.1 OVERVIEW 200
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 200
FIGURE 27 OVERVIEW OF STRATEGIES ADOPTED BY KEY RADIOTHERAPY PLAYERS (2020 TO 2023) 201
12.3 REVENUE ANALYSIS 202
FIGURE 28 REVENUE ANALYSIS OF TOP FIVE PLAYERS, 2019–2022 202
12.4 MARKET SHARE ANALYSIS 202
FIGURE 29 RADIOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022 202
12.5 COMPANY EVALUATION MATRIX 203
12.5.1 STARS 203
12.5.2 EMERGING LEADERS 203
12.5.3 PERVASIVE PLAYERS 203
12.5.4 PARTICIPANTS 203
FIGURE 30 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX, 2022 204
12.5.5 COMPANY FOOTPRINT 205
TABLE 199 PRODUCT FOOTPRINT (18 COMPANIES) 205
TABLE 200 REGIONAL FOOTPRINT (18 COMPANIES) 206
TABLE 201 COMPANY FOOTPRINT (18 COMPANIES) 207
12.6 START-UP/SME EVALUATION MATRIX 207
12.6.1 PROGRESSIVE COMPANIES 207
12.6.2 RESPONSIVE COMPANIES 208
12.6.3 DYNAMIC COMPANIES 208
12.6.4 STARTING BLOCKS 208
FIGURE 31 RADIOTHERAPY MARKET: START-UP/SME EVALUATION MATRIX, 2022 208
12.6.5 COMPETITIVE BENCHMARKING 209
TABLE 202 RADIOTHERAPY MARKET: DETAILED LIST OF KEY START-UPS/SMES 209
12.7 COMPETITIVE SCENARIO AND TRENDS 210
12.7.1 PRODUCT LAUNCHES & APPROVALS 210
12.7.2 DEALS 210
12.7.3 OTHER DEVELOPMENTS 211

13 COMPANY PROFILES 212
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS 212
13.1.1 SIEMENS HEALTHINEERS GMBH (VARIAN MEDICAL SYSTEMS, INC.) 212
TABLE 203 SIEMENS HEALTHINEERS GMBH: COMPANY OVERVIEW 212
FIGURE 32 SIEMENS HEALTHINEERS GMBH: COMPANY SNAPSHOT (2022) 213
13.1.2 ELEKTA 219
TABLE 204 ELEKTA: COMPANY OVERVIEW 219
FIGURE 33 ELEKTA: COMPANY SNAPSHOT (2022) 220
13.1.3 ACCURAY INCORPORATED 226
TABLE 205 ACCURAY INCORPORATED: COMPANY OVERVIEW 226
FIGURE 34 ACCURAY INCORPORATED: COMPANY SNAPSHOT (2023) 227
13.1.4 IBA WORLDWIDE (ION BEAM APPLICATIONS SA) 231
TABLE 206 IBA WORLDWIDE: COMPANY OVERVIEW 231
FIGURE 35 IBA WORLDWIDE: COMPANY SNAPSHOT (FY 2022) 232
13.1.5 VIEWRAY TECHNOLOGIES, INC. 236
TABLE 207 VIEWRAY TECHNOLOGIES, INC.: COMPANY OVERVIEW 236
FIGURE 36 VIEWRAY TECHNOLOGIES, INC.: COMPANY SNAPSHOT (FY 2022) 237
13.1.6 PERSPECTIVE THERAPEUTICS, INC. 241
TABLE 208 PERSPECTIVE THERAPEUTICS, INC.: COMPANY OVERVIEW 241
FIGURE 37 PERSPECTIVE THERAPEUTICS, INC.: COMPANY SNAPSHOT (FY 2022) 241
13.1.7 HITACHI LTD. 243
TABLE 209 HITACHI LTD.: COMPANY OVERVIEW 243
FIGURE 38 HITACHI LTD.: COMPANY SNAPSHOT (FY 2022) 244
13.1.8 SUMITOMO HEAVY INDUSTRIES LTD. 246
TABLE 210 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY OVERVIEW 246
FIGURE 39 SUMITOMO HEAVY INDUSTRIES: COMPANY SNAPSHOT (FY 2022) 247
13.1.9 CARL ZEISS MEDITEC AG 249
TABLE 211 CARL ZEISS MEDITEC AG: COMPANY OVERVIEW 249
FIGURE 40 CARL ZEISS MEDITEC AG: COMPANY SNAPSHOT (2021) 250
13.1.10 MIM SOFTWARE INC. 252
TABLE 212 MIM SOFTWARE INC.: COMPANY OVERVIEW 252
13.1.11 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 254
TABLE 213 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW 254
13.1.12 PROVISION HEALTHCARE 256
TABLE 214 PROVISION HEALTHCARE: COMPANY OVERVIEW 256
13.1.13 MEVION MEDICAL SYSTEMS 257
TABLE 215 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 257
13.1.14 OPTIVUS PROTON THERAPY, INC. 260

TABLE 216 OPTIVUS PROTON THERAPY: COMPANY OVERVIEW 260
13.1.15 P-CURE 261
TABLE 217 P-CURE: COMPANY OVERVIEW 261
13.1.16 INTRAOP MEDICAL, INC. 263
TABLE 218 INTRAOP MEDICAL, INC.: COMPANY OVERVIEW 263
13.1.17 BEBIG MEDICAL 264
TABLE 219 BEBIG MEDICAL: COMPANY OVERVIEW 264
13.1.18 KONINKLIJKE PHILIPS N.V. 266
TABLE 220 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 266
FIGURE 41 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 267
13.1.19 RAYSEARCH LABORATORIES 268
TABLE 221 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 268
FIGURE 42 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2022) 269
13.1.20 THERAGENICS 272
TABLE 222 THERAGENICS CORPORATION: COMPANY OVERVIEW 272
13.2 OTHER PLAYERS 273
13.2.1 PROTOM INTERNATIONAL 273
13.2.2 DOSISOFT SA 273
13.2.3 ISOAID 274
13.2.4 MAGNETTX ONCOLOGY SOLUTIONS LTD. 274
13.2.5 BRAINLAB AG 275
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 276
14.1 DISCUSSION GUIDE 276
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 282
14.3 CUSTOMIZATION OPTIONS 284
14.4 RELATED REPORTS 284
14.5 AUTHOR DETAILS 285

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の放射線療法市場（～2028年）：種類別（製品、サービス）、技術別（MRIリニアック、定位、粒子線治療、コバルト60線治療）、処置別（IMRT、IGRT、3D-CRT、LDR、HDR）、用途別（前立腺、乳房、肺）、エンドユーザー別（病院）、地域別(Radiotherapy Market by Type (Product, Service), Technology (MRI LINAC, Stereotactic, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT, 3D-CRT, LDR, HDR), Application (Prostate, Breast, Lung), End User (Hospital) & Region - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp